Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05384457
Other study ID # B1152021000029
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date August 22, 2022
Est. completion date November 1, 2025

Study information

Verified date October 2022
Source Hasselt University
Contact Sim Klaps
Phone +32(0)11268467
Email sim.klaps@uhasselt.be
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This randomized controlled trial aims to investigate 1) the effects of high intensity training (HIT) compared to moderate intensity training (MIT) on diaphragm muscle strength, -endurance, -fatigue and -activation, 2) to which extent these changes in diaphragm functioning are related to changes in cardiorespiratory fitness, postural control, pain and disability after HIT versus MIT, 3) to which extent depressive mood and anxiety moderate the effects of HIT on diaphragm functioning in persons with chronic nonspecific low back pain (CNSLBP). The investigators hypothize that HIT improves diaphragm functioning more compared to MIT in persons with CNSLBP.


Description:

Low back pain is the number one cause of disability worldwide with important socio-economic implications. In Belgium, 7 out of 10 persons will suffer from low back pain during their life, and 29% of all sick leave days are due to it. Chronic low back pain is defined as persistent pain for a period of minimal 12 weeks. In 85-90% of the CLBP cases, the pain cannot be attributed to a definitive underlying pathoanatomical cause, and is therefore labelled as chronic nonspecific low back pain (CNSLBP). International guidelines recommend exercise therapy as the first-choice treatment for CNSLBP. A crucial factor within this context is exercise intensity. Indeed, multimodal high intensity training (HIT) leads to higher improvements in disability and cardiorespiratory fitness compared to moderate intensity training (MIT) in persons with CNSLBP. However, the underlying mechanisms for the additional value of a HIT approach remain largely unknown. Interestingly, low back pain is associated with impairments in diaphragm function, as the diaphragm is not only a principal inspiratory muscle, but also plays an essential role in postural control. The latter is a key factor in the development and maintenance of CNSLBP. In this randomized controlled trial, 64 persons with CNSLBP will be recruited through local distribution of flyers and adverts on social media. The sample size calculation is based on (1) the therapeutic effects of a 12-week HIT program (compared to a MIT program) on the maximal oxygen uptake (VO2max) in persons with CNSLBP and (2) the therapeutic effects of a 8-week high-intensity inspiratory muscle training program (compared to a low-intensity inspiratory muscle training program) on the maximal inspiratory pressure (MIP) in persons with CNSLBP. These outcomes were chosen as they relate to the respiratory system and are thus most fitting to indicate possible effects on diaphragm functioning. The sample size calculation is based on the requirement of a minimal clinically important difference of 3-3.5ml/kg/min (VO2max) and 17.2 H2O (MIP). The power calculation resulted in a total of 63 persons. Therefore, the investigators plan to recruit 64 patients. Participants will be randomly assigned to a HIT program or a MIT program. Primary outcomes are diaphragm muscle strength, -endurance, -fatigue and - activation. Secondary outcomes are cardiorespiratory fitness, postural control, pain, disability, depressive mood and anxiety. Primary and secondary outcomes will be assessed at 5 timepoints (0 weeks, 6 weeks, 12 weeks, 3 months after intervention, 12 months after intervention). To analyze the data, JMP Pro (15.2 SAS Institute Inc, Cary, USA) will be used. Descriptive statistics will be used to display baseline group characteristics. To evaluate between-group differences (i.e. the effectiveness of the HIT vs MIT intervention), a linear mixed model will be fitted with 'time' and 'group' as covariates, and incorporated random intercepts for the participants to account for the within-subject variation. To evaluate associations between diaphragm functioning and predictors/mediators for therapy success, correlations and multivariate regression analysis will be used.


Recruitment information / eligibility

Status Recruiting
Enrollment 64
Est. completion date November 1, 2025
Est. primary completion date June 1, 2025
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criterian (CNSLBP patients): - Dutch-speaking - Adults (age 18-65 years) - Chronic low back pain (i.e. pain localized below the costal margin and above the inferior gluteal folds, with or without referred leg pain for a period of at least twelve weeks), with a non-specific origin (i.e. pain of a nociceptive mechanical nature, not attributable to a recognizable, known, specific pathology, e.g. infection, tumour, osteoporosis, fracture, structural deformity, inflammatory disorder, radicular syndrome, or cauda equina syndrome) Exclusion Criteria (CNSLBP patients): - History of spinal fusion - A musculoskeletal disorder aside from chronic nonspecific low back pain that could affect the correct execution of the therapy program - Baseline characteristics that could affect the evaluation of the outcomes (a pacemaker, a chronic obstructive respiratory disorder, or known balance/vestibular problems) - Severe comorbidities (e.g., paresis or sensory disturbances of neurological origin, diabetes mellitus, rheumatoid arthritis) - Ongoing compensation claims - Negative advice from the general practitioner regarding sports medical screening - Pregnancy - Persons that are not able to attend regular appointments Inclusion Criteria (healthy volunteers): - Dutch-speaking - Adults (age 18-65 years) - No acute or chronic complaints Exclusion Criteria (healthy volunteers): - History of spinal fusion - Baseline characteristics that could affect the evaluation of the outcomes (a pacemaker, a chronic obstructive respiratory disorder, or known balance/vestibular problems) - Severe comorbidities (e.g., paresis or sensory disturbances of neurological origin, diabetes mellitus, rheumatoid arthritis) - Ongoing compensation claims - Negative advice from the general practitioner regarding sports medical screening - Pregnancy

Study Design


Related Conditions & MeSH terms


Intervention

Other:
High intensity training
Participants will follow an exercise therapy program consisting of cardiorespiratory training, limb strength training and core muscle training.
Moderate intensity training
Participants will follow an exercise therapy program consisting of cardiorespiratory training, limb strength training and core muscle training.

Locations

Country Name City State
Belgium Hasselt University Diepenbeek Limburg

Sponsors (3)

Lead Sponsor Collaborator
Hasselt University KU Leuven, Maastricht University

Country where clinical trial is conducted

Belgium, 

Outcome

Type Measure Description Time frame Safety issue
Primary Diaphragm strength Maximal inspiratory pressure (MIP) is a reliable measure to quantify inspiratory muscle strength. MIP will be measured at residual volume according to the method of Black and Hyatt using an electronic pressure transducer (POWERbreathe International Ltd., type KH2, Warwickshire, UK). A minimum of five repetitions will be performed, and tests will be repeated until there is less than 5% difference between the best and second-best test. The highest pressure sustained over 1 s will be defined as MIP, and compared with reference values. PRE (baseline)
Primary Diaphragm strength Maximal inspiratory pressure (MIP) is a reliable measure to quantify inspiratory muscle strength. MIP will be measured at residual volume according to the method of Black and Hyatt using an electronic pressure transducer (POWERbreathe International Ltd., type KH2, Warwickshire, UK). A minimum of five repetitions will be performed, and tests will be repeated until there is less than 5% difference between the best and second-best test. The highest pressure sustained over 1 s will be defined as MIP. MID (6 weeks)
Primary Diaphragm strength Maximal inspiratory pressure (MIP) is a reliable measure to quantify inspiratory muscle strength. MIP will be measured at residual volume according to the method of Black and Hyatt using an electronic pressure transducer (POWERbreathe International Ltd., type KH2, Warwickshire, UK). A minimum of five repetitions will be performed, and tests will be repeated until there is less than 5% difference between the best and second-best test. The highest pressure sustained over 1 s will be defined as MIP. POST (12 weeks)
Primary Diaphragm strength Maximal inspiratory pressure (MIP) is a reliable measure to quantify inspiratory muscle strength. MIP will be measured at residual volume according to the method of Black and Hyatt using an electronic pressure transducer (POWERbreathe International Ltd., type KH2, Warwickshire, UK). A minimum of five repetitions will be performed, and tests will be repeated until there is less than 5% difference between the best and second-best test. The highest pressure sustained over 1 s will be defined as MIP. FU1 (3 months follow-up)
Primary Diaphragm strength Maximal inspiratory pressure (MIP) is a reliable measure to quantify inspiratory muscle strength. MIP will be measured at residual volume according to the method of Black and Hyatt using an electronic pressure transducer (POWERbreathe International Ltd., type KH2, Warwickshire, UK). A minimum of five repetitions will be performed, and tests will be repeated until there is less than 5% difference between the best and second-best test. The highest pressure sustained over 1 s will be defined as MIP. FU2 (12 months follow-up)
Primary Diaphragm endurance Participants will undergo an inspiratory resistive loading protocol at a fixed intensity of 80% of MIP (POWERbreathe International Ltd., type KH2, Warwickshire, UK). The participants will be instructed to inhale maximally and as rapidly as possible at a frequency of 15 breaths/minute and a 0.5 duty cycle. The time to task failure will be recorded as the inspiratory muscle endurance time. PRE (baseline)
Primary Diaphragm endurance Participants will undergo an inspiratory resistive loading protocol at a fixed intensity of 80% of MIP (POWERbreathe International Ltd., type KH2, Warwickshire, UK). The participants will be instructed to inhale maximally and as rapidly as possible at a frequency of 15 breaths/minute and a 0.5 duty cycle. The time to task failure will be recorded as the inspiratory muscle endurance time. POST (12 weeks)
Primary Diaphragm fatigue Diaphragm fatigue is defined as a reduction in the ability to produce force/pressure following contractile activity. First, MIP will be measured using an electronic pressure transducer (POWERbreathe International Ltd., type KH2, Warwickshire, UK). Then, the participant will perform a maximal cardiopulmonary exercise test (CPET). After the CPET, the MIP-measurement will be repeated. The difference between the MIP before and after the CPET will be used as a measure of diaphragm fatigue. PRE (baseline)
Primary Diaphragm fatigue Diaphragm fatigue is defined as a reduction in the ability to produce force/pressure following contractile activity. First, MIP will be measured using an electronic pressure transducer ((POWERbreathe International Ltd., type KH2, Warwickshire, UK). Then, the participant will perform a maximal cardiopulmonary exercise test (CPET). After the CPET, the MIP-measurement will be repeated. The difference between the MIP before and after the CPET will be used as a measure of diaphragm fatigue. MID (6 weeks)
Primary Diaphragm fatigue Diaphragm fatigue is defined as a reduction in the ability to produce force/pressure following contractile activity. First, MIP will be measured using an electronic pressure transducer (POWERbreathe International Ltd., type KH2, Warwickshire, UK). Then, the participant will perform a maximal cardiopulmonary exercise test (CPET). After the CPET, the MIP-measurement will be repeated. The difference between the MIP before and after the CPET will be used as a measure of diaphragm fatigue. POST (12 weeks)
Primary Diaphragm fatigue Diaphragm fatigue is defined as a reduction in the ability to produce force/pressure following contractile activity. First, MIP will be measured using an electronic pressure transducer (POWERbreathe International Ltd., type KH2, Warwickshire, UK). Then, the participant will perform a maximal cardiopulmonary exercise test (CPET). After the CPET, the MIP-measurement will be repeated. The difference between the MIP before and after the CPET will be used as a measure of diaphragm fatigue. FU1 (3 months follow-up)
Primary Diaphragm fatigue Diaphragm fatigue is defined as a reduction in the ability to produce force/pressure following contractile activity. First, MIP will be measured using an electronic pressure transducer (POWERbreathe International Ltd., type KH2, Warwickshire, UK). Then, the participant will perform a maximal cardiopulmonary exercise test (CPET). After the CPET, the MIP-measurement will be repeated. The difference between the MIP before and after the CPET will be used as a measure of diaphragm fatigue. FU2 (12 months follow-up)
Primary Diaphragm activation (amplitude) Diaphragm activation will be measured in terms of electromyography (EMG) amplitude. Surface EMG will be acquired throughout the postural control tasks and cardiopulmonary exercise test to measure muscle activation from the costal diaphragm/intercostals, scalene, parasternal intercostal, and sternocleidomastoid. PRE (baseline)
Primary Diaphragm activation (amplitude) Diaphragm activation will be measured in terms of electromyography (EMG) amplitude. Surface EMG will be acquired throughout the postural control tasks and cardiopulmonary exercise test to measure muscle activation from the costal diaphragm/intercostals, scalene, parasternal intercostal, and sternocleidomastoid. MID (6 weeks)
Primary Diaphragm activation (amplitude) Diaphragm activation will be measured in terms of electromyography (EMG) amplitude. Surface EMG will be acquired throughout the postural control tasks and cardiopulmonary exercise test to measure muscle activation from the costal diaphragm/intercostals, scalene, parasternal intercostal, and sternocleidomastoid. POST (12 weeks)
Primary Diaphragm activation (amplitude) Diaphragm activation will be measured in terms of electromyography (EMG) amplitude. Surface EMG will be acquired throughout the postural control tasks and cardiopulmonary exercise test to measure muscle activation from the costal diaphragm/intercostals, scalene, parasternal intercostal, and sternocleidomastoid. FU1 (3 months follow-up)
Primary Diaphragm activation (amplitude) Diaphragm activation will be measured in terms of electromyography (EMG) amplitude. Surface EMG will be acquired throughout the postural control tasks and cardiopulmonary exercise test to measure muscle activation from the costal diaphragm/intercostals, scalene, parasternal intercostal, and sternocleidomastoid. FU2 (12 months follow-up)
Primary Diaphragm activation (timing) Diaphragm activation will be measured in terms of electromyography (EMG) timing. Surface EMG will be acquired throughout the postural control tasks and cardiopulmonary exercise test to measure muscle activation from the costal diaphragm/intercostals, scalene, parasternal intercostal, and sternocleidomastoid. PRE (baseline)
Primary Diaphragm activation (timing) Diaphragm activation will be measured in terms of electromyography (EMG) timing. Surface EMG will be acquired throughout the postural control tasks and cardiopulmonary exercise test to measure muscle activation from the costal diaphragm/intercostals, scalene, parasternal intercostal, and sternocleidomastoid. MID (6 weeks)
Primary Diaphragm activation (timing) Diaphragm activation will be measured in terms of electromyography (EMG) timing. Surface EMG will be acquired throughout the postural control tasks and cardiopulmonary exercise test to measure muscle activation from the costal diaphragm/intercostals, scalene, parasternal intercostal, and sternocleidomastoid. POST (12 weeks)
Primary Diaphragm activation (timing) Diaphragm activation will be measured in terms of electromyography (EMG) timing. Surface EMG will be acquired throughout the postural control tasks and cardiopulmonary exercise test to measure muscle activation from the costal diaphragm/intercostals, scalene, parasternal intercostal, and sternocleidomastoid. FU1 (3 months follow-up)
Primary Diaphragm activation (timing) Diaphragm activation will be measured in terms of electromyography (EMG) timing. Surface EMG will be acquired throughout the postural control tasks and cardiopulmonary exercise test to measure muscle activation from the costal diaphragm/intercostals, scalene, parasternal intercostal, and sternocleidomastoid. FU2 (12 months follow-up)
Secondary Modified Oswestry Disability Index (MODI) The Modified Oswestry Disability Index is a valid and reliable questionnaire for evaluating constraints experienced by people in their daily activities due to chronic low back pain. It consists of ten items scored on a five-point scale. The total score is expressed in percentage (min. 0%, max. 100%) and displays the degree of functional limitation. A higher score indicates a higher degree of functional limitation. PRE (baseline)
Secondary Modified Oswestry Disability Index (MODI) The Modified Oswestry Disability Index is a valid and reliable questionnaire for evaluating constraints experienced by people in their daily activities due to chronic low back pain. It consists of ten items scored on a five-point scale. The total score is expressed in percentage (min. 0%, max. 100%) and displays the degree of functional limitation. A higher score indicates a higher degree of functional limitation. MID (6 weeks)
Secondary Modified Oswestry Disability Index (MODI) The Modified Oswestry Disability Index is a valid and reliable questionnaire for evaluating constraints experienced by people in their daily activities due to chronic low back pain. It consists of ten items scored on a five-point scale. The total score is expressed in percentage (min. 0%, max. 100%) and displays the degree of functional limitation. A higher score indicates a higher degree of functional limitation. POST (12 weeks)
Secondary Modified Oswestry Disability Index (MODI) The Modified Oswestry Disability Index is a valid and reliable questionnaire for evaluating constraints experienced by people in their daily activities due to chronic low back pain. It consists of ten items scored on a five-point scale. The total score is expressed in percentage (min. 0%, max. 100%) and displays the degree of functional limitation. A higher score indicates a higher degree of functional limitation. FU1 (3 months follow-up)
Secondary Modified Oswestry Disability Index (MODI) The Modified Oswestry Disability Index is a valid and reliable questionnaire for evaluating constraints experienced by people in their daily activities due to chronic low back pain. It consists of ten items scored on a five-point scale. The total score is expressed in percentage (min. 0%, max. 100%) and displays the degree of functional limitation. A higher score indicates a higher degree of functional limitation. FU2 (12 months follow-up)
Secondary Brief Pain Inventory (BPI) The Brief Pain Inventory assesses the severity of pain, its impact on functioning, the location of pain, pain medications, and the amount of pain relief in the past 24 hours. The body chart of this questionnaire will be used to record the extent of pain, using the pain drawing method. The extent of pain might indicate the presence of widespread pain, which has been associated with altered nociceptive pain processing in chronic joint pain. The BPI scale defines pain as follows:
Worst Pain Score: 1 - 4 = Mild Pain
Worst Pain Score: 5 - 6 = Moderate Pain
Worst Pain Score: 7 - 10 = Severe Pain
PRE (baseline)
Secondary Brief Pain Inventory (BPI) The Brief Pain Inventory assesses the severity of pain, its impact on functioning, the location of pain, pain medications, and the amount of pain relief in the past 24 hours. The body chart of this questionnaire will be used to record the extent of pain, using the pain drawing method. The extent of pain might indicate the presence of widespread pain, which has been associated with altered nociceptive pain processing in chronic joint pain. The BPI scale defines pain as follows:
Worst Pain Score: 1 - 4 = Mild Pain
Worst Pain Score: 5 - 6 = Moderate Pain
Worst Pain Score: 7 - 10 = Severe Pain
MID (6 weeks)
Secondary Brief Pain Inventory (BPI) The Brief Pain Inventory assesses the severity of pain, its impact on functioning, the location of pain, pain medications, and the amount of pain relief in the past 24 hours. The body chart of this questionnaire will be used to record the extent of pain, using the pain drawing method. The extent of pain might indicate the presence of widespread pain, which has been associated with altered nociceptive pain processing in chronic joint pain. The BPI scale defines pain as follows:
Worst Pain Score: 1 - 4 = Mild Pain
Worst Pain Score: 5 - 6 = Moderate Pain
Worst Pain Score: 7 - 10 = Severe Pain
POST (12 weeks)
Secondary Brief Pain Inventory (BPI) The Brief Pain Inventory assesses the severity of pain, its impact on functioning, the location of pain, pain medications, and the amount of pain relief in the past 24 hours. The body chart of this questionnaire will be used to record the extent of pain, using the pain drawing method. The extent of pain might indicate the presence of widespread pain, which has been associated with altered nociceptive pain processing in chronic joint pain. The BPI scale defines pain as follows:
Worst Pain Score: 1 - 4 = Mild Pain
Worst Pain Score: 5 - 6 = Moderate Pain
Worst Pain Score: 7 - 10 = Severe Pain
FU1 (3 months follow-up)
Secondary Brief Pain Inventory (BPI) The Brief Pain Inventory assesses the severity of pain, its impact on functioning, the location of pain, pain medications, and the amount of pain relief in the past 24 hours. The body chart of this questionnaire will be used to record the extent of pain, using the pain drawing method. The extent of pain might indicate the presence of widespread pain, which has been associated with altered nociceptive pain processing in chronic joint pain. The BPI scale defines pain as follows:
Worst Pain Score: 1 - 4 = Mild Pain
Worst Pain Score: 5 - 6 = Moderate Pain
Worst Pain Score: 7 - 10 = Severe Pain
FU2 (12 months follow-up)
Secondary Beck Depression Inventory (BDI) The Beck Depression Inventory is widely used as a self-reported questionnaire for assessing depression in patients with chronic pain. It consists of 21 items scored on a four-point scale (0-3). Item scores are summed to obtain the total score, with a higher total score indicating greater depression. PRE (baseline)
Secondary Beck Depression Inventory (BDI) The Beck Depression Inventory is widely used as a self-reported questionnaire for assessing depression in patients with chronic pain. It consists of 21 items scored on a four-point scale (0-3). Item scores are summed to obtain the total score, with a higher total score indicating greater depression. POST (12 weeks)
Secondary Beck Depression Inventory (BDI) The Beck Depression Inventory is widely used as a self-reported questionnaire for assessing depression in patients with chronic pain. It consists of 21 items scored on a four-point scale (0-3). Item scores are summed to obtain the total score, with a higher total score indicating greater depression. FU2 (12 months follow-up)
Secondary State-Trait Anxiety Inventory (STAI) The State-Trait Anxiety Inventory is a questionnaire for assessing state anxiety (i.e. anxiety about an event) and trait anxiety (i.e. anxiety as a personal characteristic). It consists of 40 items scored on a four-point scale. Item scores are added to obtain the total score. The score of the STAI varies from a minimum score of 20 to a maximum score of 80 on both the STAI-state and STAI-trait subscales. STAI scores are commonly classified as "no or low anxiety" (20-37), "moderate anxiety" (38-44), and "high anxiety" (45-80). PRE (baseline)
Secondary State-Trait Anxiety Inventory (STAI) The State-Trait Anxiety Inventory is a questionnaire for assessing state anxiety (i.e. anxiety about an event) and trait anxiety (i.e. anxiety as a personal characteristic). It consists of 40 items scored on a four-point scale. Item scores are added to obtain the total score. The score of the STAI varies from a minimum score of 20 to a maximum score of 80 on both the STAI-state and STAI-trait subscales. STAI scores are commonly classified as "no or low anxiety" (20-37), "moderate anxiety" (38-44), and "high anxiety" (45-80). POST (12 weeks)
Secondary State-Trait Anxiety Inventory (STAI) The State-Trait Anxiety Inventory is a questionnaire for assessing state anxiety (i.e. anxiety about an event) and trait anxiety (i.e. anxiety as a personal characteristic). It consists of 40 items scored on a four-point scale. Item scores are added to obtain the total score. The score of the STAI varies from a minimum score of 20 to a maximum score of 80 on both the STAI-state and STAI-trait subscales. STAI scores are commonly classified as "no or low anxiety" (20-37), "moderate anxiety" (38-44), and "high anxiety" (45-80). FU2 (12 months follow-up)
Secondary Relative proprioceptive weighting ratio A force plate will measure center of pressure (COP) displacement in response to ankle and lumbar muscle vibration during upright standing. If a person relies on proprioception from the vibrated muscle, an illusion of loss of balance will occur. To compensate, participants will move their COP in the opposite direction. When the triceps surae muscles are vibrated, a postural sway in a backward direction is expected, whereas during lumbar paraspinal muscle vibration, a forward postural body sway is expected. The amount of COP displacement during local vibration may represent the extent to which a person makes use of the proprioceptive signals of the vibrated muscles to maintain the upright posture. Reliance on ankle vs. lumbar proprioception will be calculated as the Relative Proprioceptive Weighting (RPW) ratio: RPW= AbsAnkle/(AbsAnkle + AbsLumbar). 'AbsAnkle' and 'AbsLumbar' refer to the absolute COP displacement during ankle and lumbar muscle vibration, respectively. PRE (baseline)
Secondary Relative proprioceptive weighting ratio A force plate will measure center of pressure (COP) displacement in response to ankle and lumbar muscle vibration during upright standing. If a person relies on proprioception from the vibrated muscle, an illusion of loss of balance will occur. To compensate, participants will move their COP in the opposite direction. When the triceps surae muscles are vibrated, a postural sway in a backward direction is expected, whereas during lumbar paraspinal muscle vibration, a forward postural body sway is expected. The amount of COP displacement during local vibration may represent the extent to which a person makes use of the proprioceptive signals of the vibrated muscles to maintain the upright posture. Reliance on ankle vs. lumbar proprioception will be calculated as the Relative Proprioceptive Weighting (RPW) ratio: RPW= AbsAnkle/(AbsAnkle + AbsLumbar). 'AbsAnkle' and 'AbsLumbar' refer to the absolute COP displacement during ankle and lumbar muscle vibration, respectively. MID (6 weeks)
Secondary Relative proprioceptive weighting ratio A force plate will measure center of pressure (COP) displacement in response to ankle and lumbar muscle vibration during upright standing. If a person relies on proprioception from the vibrated muscle, an illusion of loss of balance will occur. To compensate, participants will move their COP in the opposite direction. When the triceps surae muscles are vibrated, a postural sway in a backward direction is expected, whereas during lumbar paraspinal muscle vibration, a forward postural body sway is expected. The amount of COP displacement during local vibration may represent the extent to which a person makes use of the proprioceptive signals of the vibrated muscles to maintain the upright posture. Reliance on ankle vs. lumbar proprioception will be calculated as the Relative Proprioceptive Weighting (RPW) ratio: RPW= AbsAnkle/(AbsAnkle + AbsLumbar). 'AbsAnkle' and 'AbsLumbar' refer to the absolute COP displacement during ankle and lumbar muscle vibration, respectively. POST (12 weeks)
Secondary Relative proprioceptive weighting ratio A force plate will measure center of pressure (COP) displacement in response to ankle and lumbar muscle vibration during upright standing. If a person relies on proprioception from the vibrated muscle, an illusion of loss of balance will occur. To compensate, participants will move their COP in the opposite direction. When the triceps surae muscles are vibrated, a postural sway in a backward direction is expected, whereas during lumbar paraspinal muscle vibration, a forward postural body sway is expected. The amount of COP displacement during local vibration may represent the extent to which a person makes use of the proprioceptive signals of the vibrated muscles to maintain the upright posture. Reliance on ankle vs. lumbar proprioception will be calculated as the Relative Proprioceptive Weighting (RPW) ratio: RPW= AbsAnkle/(AbsAnkle + AbsLumbar). 'AbsAnkle' and 'AbsLumbar' refer to the absolute COP displacement during ankle and lumbar muscle vibration, respectively. FU1 (3 months follow-up)
Secondary Relative proprioceptive weighting ratio A force plate will measure center of pressure (COP) displacement in response to ankle and lumbar muscle vibration during upright standing. If a person relies on proprioception from the vibrated muscle, an illusion of loss of balance will occur. To compensate, participants will move their COP in the opposite direction. When the triceps surae muscles are vibrated, a postural sway in a backward direction is expected, whereas during lumbar paraspinal muscle vibration, a forward postural body sway is expected. The amount of COP displacement during local vibration may represent the extent to which a person makes use of the proprioceptive signals of the vibrated muscles to maintain the upright posture. Reliance on ankle vs. lumbar proprioception will be calculated as the Relative Proprioceptive Weighting (RPW) ratio: RPW= AbsAnkle/(AbsAnkle + AbsLumbar). 'AbsAnkle' and 'AbsLumbar' refer to the absolute COP displacement during ankle and lumbar muscle vibration, respectively. FU2 (12 months follow-up)
Secondary Thermal Detection and Pain Threshold Temperatures Thermal Quantitative sensory testing (QST) will be used to investigate nociceptive stimulus processing. QST is a non-invasive examination of the somatosensory system commonly used in pain diagnosis. The Medoc Advanced Thermosensory Stimulator (TSA) - 2 system will be used to perform a standardized test protocol.
Detection and pain threshold temperatures (in °C) will be assessed locally (at the most painful site of the lower back) and remotely (at the contralateral wrist) using the TSA limits protocol:
Cold Detection Threshold (CDT)
Warmth Detection Threshold (WDT)
Cold Pain Threshold (CPT)
Heat Pain Threshold (HPT)
PRE (baseline)
Secondary Thermal Detection and Pain Threshold Temperatures Thermal Quantitative sensory testing (QST) will be used to investigate nociceptive stimulus processing. QST is a non-invasive examination of the somatosensory system commonly used in pain diagnosis. The Medoc Advanced Thermosensory Stimulator (TSA) - 2 system will be used to perform a standardized test protocol.
Detection and pain threshold temperatures (in °C) will be assessed locally (at the most painful site of the lower back) and remotely (at the contralateral wrist) using the TSA limits protocol:
Cold Detection Threshold (CDT)
Warmth Detection Threshold (WDT)
Cold Pain Threshold (CPT)
Heat Pain Threshold (HPT)
MID (6 weeks)
Secondary Thermal Detection and Pain Threshold Temperatures Thermal Quantitative sensory testing (QST) will be used to investigate nociceptive stimulus processing. QST is a non-invasive examination of the somatosensory system commonly used in pain diagnosis. The Medoc Advanced Thermosensory Stimulator (TSA) - 2 system will be used to perform a standardized test protocol.
Detection and pain threshold temperatures (in °C) will be assessed locally (at the most painful site of the lower back) and remotely (at the contralateral wrist) using the TSA limits protocol:
Cold Detection Threshold (CDT)
Warmth Detection Threshold (WDT)
Cold Pain Threshold (CPT)
Heat Pain Threshold (HPT)
POST (12 weeks)
Secondary Thermal Detection and Pain Threshold Temperatures Thermal Quantitative sensory testing (QST) will be used to investigate nociceptive stimulus processing. QST is a non-invasive examination of the somatosensory system commonly used in pain diagnosis. The Medoc Advanced Thermosensory Stimulator (TSA) - 2 system will be used to perform a standardized test protocol.
Detection and pain threshold temperatures (in °C) will be assessed locally (at the most painful site of the lower back) and remotely (at the contralateral wrist) using the TSA limits protocol:
Cold Detection Threshold (CDT)
Warmth Detection Threshold (WDT)
Cold Pain Threshold (CPT)
Heat Pain Threshold (HPT)
FU1 (3 months follow-up)
Secondary Thermal Detection and Pain Threshold Temperatures Thermal Quantitative sensory testing (QST) will be used to investigate nociceptive stimulus processing. QST is a non-invasive examination of the somatosensory system commonly used in pain diagnosis. The Medoc Advanced Thermosensory Stimulator (TSA) - 2 system will be used to perform a standardized test protocol.
Detection and pain threshold temperatures (in °C) will be assessed locally (at the most painful site of the lower back) and remotely (at the contralateral wrist) using the TSA limits protocol:
Cold Detection Threshold (CDT)
Warmth Detection Threshold (WDT)
Cold Pain Threshold (CPT)
Heat Pain Threshold (HPT)
FU2 (12 months follow-up)
Secondary Temporal Summation of Pain (TSP) Thermal Quantitative sensory testing (QST) will be used to investigate nociceptive stimulus processing. QST is a non-invasive examination of the somatosensory system commonly used in pain diagnosis. The Medoc TSA-2 system will be used to perform a standardized test protocol.
Temporal summation of pain (TSP) will be assessed at the contralateral wrist using a 2-minute tonic heat stimulus and patient-controlled temperature. Participants are presented with a tonic heat stimulus and are instructed to maintain their initial sensation for two minutes via the remote controller. To quantify temporal adaptation and temporal summation of pain, the slope and magnitude of temperature changes will be extracted and the areas under the curve will be calculated.
PRE (baseline)
Secondary Temporal Summation of Pain (TSP) Thermal Quantitative sensory testing (QST) will be used to investigate nociceptive stimulus processing. QST is a non-invasive examination of the somatosensory system commonly used in pain diagnosis. The Medoc TSA-2 system will be used to perform a standardized test protocol.
Temporal summation of pain (TSP) will be assessed at the contralateral wrist using a 2-minute tonic heat stimulus and patient-controlled temperature. Participants are presented with a tonic heat stimulus and are instructed to maintain their initial sensation for two minutes via the remote controller. To quantify temporal adaptation and temporal summation of pain, the slope and magnitude of temperature changes will be extracted and the areas under the curve will be calculated.
MID (6 weeks)
Secondary Temporal Summation of Pain (TSP) Thermal Quantitative sensory testing (QST) will be used to investigate nociceptive stimulus processing. QST is a non-invasive examination of the somatosensory system commonly used in pain diagnosis. The Medoc TSA-2 system will be used to perform a standardized test protocol.
Temporal summation of pain (TSP) will be assessed at the contralateral wrist using a 2-minute tonic heat stimulus and patient-controlled temperature. Participants are presented with a tonic heat stimulus and are instructed to maintain their initial sensation for two minutes via the remote controller. To quantify temporal adaptation and temporal summation of pain, the slope and magnitude of temperature changes will be extracted and the areas under the curve will be calculated.
POST (12 weeks)
Secondary Temporal Summation of Pain (TSP) Thermal Quantitative sensory testing (QST) will be used to investigate nociceptive stimulus processing. QST is a non-invasive examination of the somatosensory system commonly used in pain diagnosis. The Medoc TSA-2 system will be used to perform a standardized test protocol.
Temporal summation of pain (TSP) will be assessed at the contralateral wrist using a 2-minute tonic heat stimulus and patient-controlled temperature. Participants are presented with a tonic heat stimulus and are instructed to maintain their initial sensation for two minutes via the remote controller. To quantify temporal adaptation and temporal summation of pain, the slope and magnitude of temperature changes will be extracted and the areas under the curve will be calculated.
FU1 (3 months follow-up)
Secondary Temporal Summation of Pain (TSP) Thermal Quantitative sensory testing (QST) will be used to investigate nociceptive stimulus processing. QST is a non-invasive examination of the somatosensory system commonly used in pain diagnosis. The Medoc TSA-2 system will be used to perform a standardized test protocol.
Temporal summation of pain (TSP) will be assessed at the contralateral wrist using a 2-minute tonic heat stimulus and patient-controlled temperature. Participants are presented with a tonic heat stimulus and are instructed to maintain their initial sensation for two minutes via the remote controller. To quantify temporal adaptation and temporal summation of pain, the slope and magnitude of temperature changes will be extracted and the areas under the curve will be calculated.
FU2 (12 months follow-up)
Secondary Conditioned Pain Modulation (CPM) Thermal Quantitative sensory testing (QST) will be used to investigate nociceptive stimulus processing. The Medoc TSA-2 system will be used to perform a standardized test protocol.
Conditioned pain modulation will be evaluated using a Dual-Thermode program with two different stimuli:
Test stimulus: this heat stimulus will be administered twice at the contralateral wrist. Once on its own before administering the conditioning stimulus, and once during the conditioning heat stimulus at the ipsilateral wrist.
Conditioning stimulus: this heat stimulus will be administered at the ipsilateral wrist after first applying the test stimulus.
The difference in pain intensity at the contralateral wrist during the stand-alone test stimulus and the test stimulus during the conditioning stimulus will be calculated. Pain intensity is assessed using a Numerical Pain Rating Scale (NPRS) ranging from 0 to 100, where 0 stands for "no pain", and 100 for "worst imaginable pain".
PRE (baseline)
Secondary Conditioned Pain Modulation (CPM) Thermal Quantitative sensory testing (QST) will be used to investigate nociceptive stimulus processing. The Medoc TSA-2 system will be used to perform a standardized test protocol.
Conditioned pain modulation will be evaluated using a Dual-Thermode program with two different stimuli:
Test stimulus: this heat stimulus will be administered twice at the contralateral wrist. Once on its own before administering the conditioning stimulus, and once during the conditioning heat stimulus at the ipsilateral wrist.
Conditioning stimulus: this heat stimulus will be administered at the ipsilateral wrist after first applying the test stimulus.
The difference in pain intensity at the contralateral wrist during the stand-alone test stimulus and the test stimulus during the conditioning stimulus will be calculated. Pain intensity is assessed using a Numerical Pain Rating Scale (NPRS) ranging from 0 to 100, where 0 stands for "no pain", and 100 for "worst imaginable pain".
MID (6 weeks)
Secondary Conditioned Pain Modulation (CPM) Thermal Quantitative sensory testing (QST) will be used to investigate nociceptive stimulus processing. The Medoc TSA-2 system will be used to perform a standardized test protocol.
Conditioned pain modulation will be evaluated using a Dual-Thermode program with two different stimuli:
Test stimulus: this heat stimulus will be administered twice at the contralateral wrist. Once on its own before administering the conditioning stimulus, and once during the conditioning heat stimulus at the ipsilateral wrist.
Conditioning stimulus: this heat stimulus will be administered at the ipsilateral wrist after first applying the test stimulus.
The difference in pain intensity at the contralateral wrist during the stand-alone test stimulus and the test stimulus during the conditioning stimulus will be calculated. Pain intensity is assessed using a Numerical Pain Rating Scale (NPRS) ranging from 0 to 100, where 0 stands for "no pain", and 100 for "worst imaginable pain".
POST (12 weeks)
Secondary Conditioned Pain Modulation (CPM) Thermal Quantitative sensory testing (QST) will be used to investigate nociceptive stimulus processing. The Medoc TSA-2 system will be used to perform a standardized test protocol.
Conditioned pain modulation will be evaluated using a Dual-Thermode program with two different stimuli:
Test stimulus: this heat stimulus will be administered twice at the contralateral wrist. Once on its own before administering the conditioning stimulus, and once during the conditioning heat stimulus at the ipsilateral wrist.
Conditioning stimulus: this heat stimulus will be administered at the ipsilateral wrist after first applying the test stimulus.
The difference in pain intensity at the contralateral wrist during the stand-alone test stimulus and the test stimulus during the conditioning stimulus will be calculated. Pain intensity is assessed using a Numerical Pain Rating Scale (NPRS) ranging from 0 to 100, where 0 stands for "no pain", and 100 for "worst imaginable pain".
FU1 (3 months follow-up)
Secondary Conditioned Pain Modulation (CPM) Thermal Quantitative sensory testing (QST) will be used to investigate nociceptive stimulus processing. The Medoc TSA-2 system will be used to perform a standardized test protocol.
Conditioned pain modulation will be evaluated using a Dual-Thermode program with two different stimuli:
Test stimulus: this heat stimulus will be administered twice at the contralateral wrist. Once on its own before administering the conditioning stimulus, and once during the conditioning heat stimulus at the ipsilateral wrist.
Conditioning stimulus: this heat stimulus will be administered at the ipsilateral wrist after first applying the test stimulus.
The difference in pain intensity at the contralateral wrist during the stand-alone test stimulus and the test stimulus during the conditioning stimulus will be calculated. Pain intensity is assessed using a Numerical Pain Rating Scale (NPRS) ranging from 0 to 100, where 0 stands for "no pain", and 100 for "worst imaginable pain".
FU2 (12 months follow-up)
See also
  Status Clinical Trial Phase
Completed NCT01659073 - Using Perfusion MRI to Measure the Dynamic Changes in Neural Activation Associated With Caloric Vestibular Stimulation N/A
Recruiting NCT05914311 - Use of Dermabond in Mitigation of Spinal Cord Stimulation (SCS) Trial Lead Migration N/A
Recruiting NCT05422456 - The Turkish Version of Functional Disability Inventory
Enrolling by invitation NCT05422443 - The Turkish Version of Pain Coping Questionnaire
Completed NCT05057988 - Virtual Empowered Relief for Chronic Pain N/A
Completed NCT04385030 - Neurostimulation and Mirror Therapy in Traumatic Brachial Plexus Injury N/A
Recruiting NCT06206252 - Can Medical Cannabis Affect Opioid Use?
Completed NCT05103319 - Simultaneous Application of Ketamine and Lidocaine During an Ambulatory Infusion Therapy as a Treatment Option in Refractory Chronic Pain Conditions
Completed NCT03687762 - Back on Track to Healthy Living Study N/A
Completed NCT04171336 - Animal-assisted Therapy for Children and Adolescents With Chronic Pain N/A
Completed NCT03179475 - Targin® for Chronic Pain Management in Patients With Spinal Cord Injury Phase 4
Completed NCT03418129 - Neuromodulatory Treatments for Pain Management in TBI N/A
Completed NCT03268551 - MEMO-Medical Marijuana and Opioids Study
Recruiting NCT06060028 - The Power of Touch. Non-Invasive C-Tactile Stimulation for Chronic Osteoarthritis Pain N/A
Recruiting NCT06204627 - TDCS* and Laterality Trainnning in Patients With Chronic Neck Pain N/A
Completed NCT05496205 - A SAD Study to Evaluate the Safety, Tolerability and PK/PD of iN1011-N17 in Healthy Volunteers Phase 1
Completed NCT00983385 - Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Chronic Low Back Pain Taking Either WHO Step I or Step II Analgesics or no Regular Analgesics Phase 3
Recruiting NCT05118204 - Randomized Trial of Buprenorphine Microdose Inductions During Hospitalization Phase 4
Terminated NCT03538444 - Repetitive Transcranial Magnetic Stimulation for Opiate Use Disorder N/A
Not yet recruiting NCT05812703 - Biometrics and Self-reported Health Changes in Adults Receiving Behavioral Treatments for Chronic Pain